毛新良

 ID10v.jpg

姓   名:毛新良

职称/职务:特聘教授、博士生导师

电子邮箱:xinliangmao@suda.edu.cn

电话: (0512) 65882152

办公地址:云轩楼2213

­­­­­­­­­­­­­­­­­­­­­

一、学习工作经历

1、学历背景:

1989.09-1994.06华中科技大学同济医学院,学士

1994.09-1997.06华中科技大学同济医学院,硕士

1997.09-2000.06北京大学公共卫生学院,博士

2、国外学习研究经历:

1998.10-1999.09日本富山医科药科大学,研究生院,博士生

2000.06-2003.08加拿大麦克马斯特大学,生物化学系,博士后

2003.08-2004.08美国斯坦福大学,医学院,博士后

2004.08-2006.05加拿大多伦多大学/安大略省肿瘤研究所,博士后

3、工作经历:

2014.06 -- 至今: 苏州大学,药学院药理学系,特聘教授,博士生导师

2009.09-2014.06 苏州大学,唐仲英血液学研究中心,特聘教授,博士生导师

2006.05-2009.09加拿大多伦多大学/安大略省肿瘤研究所,Scientific Associate

二、研究方向

1)肿瘤分子生物学:蛋白质泛素化在肿瘤发生发展和治疗中的作用。

2)肿瘤药理学:恶性肿瘤尤其是血液肿瘤的药物治疗机制。

3)抗肿瘤新药研究:以肿瘤特异性分子事件为靶标发现新的抗肿瘤小分子药物。

三、主要研究成果

   主要从事肿瘤药理研究及相关药物研发,发表SCI论文50余篇。申请美国、中国和国际专利20项。

1、论文 *通信作者)

2016

[1]       Xu X#, Han K#, Tang X, Zeng Y, Lin X, Zhao Y, Zhang Z, Cao B, Wu D, Mao X*. The ring finger protein RNF6 induces leukemia cell proliferation as a direct target of pre-B-cell leukemia homeobox 1. J Biol Chem. 2016. pii: jbc.M115.701979.

[2]       Zhang Z, Tong J, Tang X, Juan J, Cao B, Hurren R, Chen G, Taylor P, Xu X, Shi C, Du J, Hou J, Wang G, Wu D, Stewart A, Schimmer A, Moran M, Mao X*. The ubiquitin ligase HERC4 mediates c-Maf ubiquitination and delays the growth of multiple myeloma xenografts in nude mice. Blood, 2016. pii: blood-2015-07-658203.

[3]       Zhang Z#, Mao H#, Du X#, Zhu J, Xu Y, Wang S, Xu X, Ji P, Yu Y, Cao B, Han K, Hou T, Xu Z, Kong Y, Jiang G, Tang T, Qiao C, Mao X*. A novel small molecule agent displays potent anti-myeloma activity by inhibiting the JAK2-STAT3 signaling pathway. Oncotarget, 2016. doi: 10.18632/oncotarget.6974.

2015

[4]       Yuan N, Song L, Zhang S, Lin W, Cao Y, Xu F, Fang Y, Wang Z, Zhang H, Li X, Wang Z, Cai J, Wang J, Zhang Y, Mao X, Zhao W, Hu S, Chen S, Wang J. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia. Haematologica. 2015 Mar;100(3):345-56.  

[5]       Ji P, Xu X, Ma S, Fan J, Zhou Q, Mao X*, Qiao C*. Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway. ACS Med Chem Lett. 2015;6:1010-4.

[6]       Han K, Xu X, Xu Z, Chen G, Zeng Y, Zhang Z, Cao B, Kong Y, Tang X, Mao X*. SC06, a novel small molecule compound, displays preclinical activity against multiple myeloma by disrupting the mTOR signaling pathway. Sci Rep. 2015;5:12809.

[7]       Juan J#, Cheng L*, Shi M#, Liu Z, Mao X*. Poly-(allylamine hydrochloride)-coated but not poly(acrylic acid)-coated upconversion nanoparticles induce autophagy and apoptosis in human blood cancer cells. J Mater Chem B, 2015;3:5769-5776.

[8]       Zhu J, Hou T*, Mao X*. Discovery of selective phosphatidylinositol 3-kinase inhibitors to treat hematological malignancies. Drug Discovery Today. 2015; 20:988-94.

[9]       Zhu J#, Wang M#, Yu Y, Qi H, Han K, Tang J, Zhang Z, Zeng Y, Cao B, Qiao C, Zhang H, Hou T*, Mao X*. A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma. Oncotarget. 2015;6:185-95. 

2014

[10]   Shi M#, Cheng L#, Zhang Z, Liu Z*, Mao X*. Ferroferric oxide nanoparticles induce pro-survival autophagy in human blood cells by modulating the Beclin 1/Bcl-2/VPS34 complex. Int J Nanomed. 2014;10:207-16.  

[11]   Chen G#, Xu X#, Tong J, Han K, Zhang Z, Tang J, Li S, Yang C, Li J, Cao B, Zhou H, Wu D, Moran MF, Mao X*. Ubiquitination of the transcription factor c-maf is mediated by multiple lysine residues. Int J Biochem Cell Biol. 2014;57: 157–166.

[12]   Yi W, Li Q, Shen J, Ren L, Liu X, Wang Q, He S, Wu Q, Hu H, Mao X*, Zhu L*. Modulation of platelet activation and thrombus formation using a pan-PI3K inhibitor S14161. PLoS One. 2014;9:e102394.

[13]   Cao B, Li J, Zhou X, Juan J, Han K, Zhang Z, Kong Y, Wang J, Mao X*. Clioquinol induces pro-death autophagy in leukemia and myeloma cells by disrupting the mTOR signaling pathway. Sci Rep. 2014;4:5749.

[14]   Zhu J, Wang M, Cao B, Hou T*, Mao X*. Targeting the phosphatidylinositol 3-Kinase/AKT Pathway for the treatment of multiple myeloma. Curr Med Chem. 2014;21:3173-87.

[15]   Tang J#, Zhu J#, Yu Y, Zhang Z, Chen G, Zhou X, Qiao C, Hou T*, Mao X*. A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity in multiple myeloma in vitro and in vivo. Oncotarget, 2014;5:3836-48.

[16]   Shi M#, Zhou X#, Zhang Z, Wang M, Chen G,  Han K, Cao B, Liu Z, Mao X*. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3. Toxicol Lett, 2014; 228:133-9.

[17]   Xu X#, Zhang J#, Han K, Zhang Z, Chen G, Zhang J, Mao X*, Cao B*. Natural pesticide dihydrorotenone arrests human plasma cancer cells at the G0/G1 phase of the cell cycle. J Biochem Mol Toxicol. 2014;28:232-8.

[18]   Zhu J, Pan P, Li Y, Wang M, Li D, Cao B, Mao X*, Hou T*. Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors. Mol Biosys. 2014;10:454-66.

[19]   Li J#, Zhu J#, Cao B, Mao X*. The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma. Curr Pharm Des. 2014; 20:125-35.

[20]   Han K, Xu X, Chen G, Zeng Y, Zhu J, Du X, Zhang Z, Cao B, Liu Z, Mao X*. Identification of a promising PI3K inhibitor for the treatment of multiple myeloma through the structural optimization. J Hematol Oncol. 2014;7(1): 9.

[21]   Chen G, Han K, Xu X, Du X, Zhang Z, Tang J, Shi M, Wang M, Li J, Cao B, Mao X*. An anti-leishmanial thiadiazine agent induces multiple myeloma cell apoptosis by suppressing the nuclear factor kappaB signaling pathway. Brit J Cancer. 2014;110: 63-70.

2013

[22]   Cao B, Li J, Zhu J, Shen M, Han K, Zhang Z, Yu Y, Wang Y, Wu D, Chen S, Sun A, Tang X, Zhao Y, Qiao C, Hou T, Mao X*. The anti-parasitic clioquinol induces apoptosis in leukemia and myeloma cells by inhibiting histone deacetylase activity. J Biol Chem. 2013;288:34181-9.

[23]   Li J#, Cao B#, Zhou S, Zhu J, Zhang Z, Hou J, and Mao X*. Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K/AKT signaling. Eur J Hematol. 2013;91:514-21.

[24]   Zhang J#, Tang J#, Cao B, Zhang Z, Li J, Schimmer AD, He S, Mao X*. The natural pesticide dihydrorotenone induces human plasma cell apoptosis by triggering endoplasmic reticulum stress and activating p38 signaling pathway. PLoS One. 2013; 8(7):e69911.

[25]   Zhang Z#, Du X#, Cao B, Zhao C, Zhao Y, Mao X*. The anti-depressant amitriptyline displays potent therapeutic activity against multiple myeloma. Anticancer Drugs. 2013; 24(8):792-8.

[26]   Liu F, He Y, Liang Y, Wen L, Zhu Y, Wu Y, Zhao L, Li Y, Mao X,Liu H. PI3-kinase inhibition synergistically promoted the anti-tumor effect of lupeol in hepatocellular carcinoma.  Cancer Cell Int. 2013;13:108.

[27]   Yin SQ, Shi M, Kong TT, Zhang CM, Han K, Cao B, Zhang Z, Du X, Tang LQ, Mao X*, Liu ZP*. Preparation of S14161 and its analogues and the discovery of 6-bromo-8-ethoxy-3-nitro-2H-chromene as a more potent antitumor agent in vitro. Bioorg Med Chem Lett. 2013 Jun 1;23(11):3314-9.

[28]   Zhang Z, Song L, Dong J, Guo D, Du X, Cao B, Zhang Y, Gu N, Mao X*. A promising combo gene delivery system developed from (3-aminopropyl)triethoxysilane-modified iron oxide nanoparticles and cationic polymers. J Nanopart Res. 2013; 15, Article No. 1659. DOI: 10.1007/s11051-013-1659-5.

[29]   Mao X*. Targeting the ubiquitin-proteasome pathway-current perspectives and future directions. Curr Pharm Des. 2013;19: 3173-3174.

[30]   Cao B, Li J, Mao X*. Dissecting bortezomib: development, application, adverse effects and future direction. Curr Pharm Des. 2013;19: 3190-3200.

2012

[31]   Ling C#, Chen G#, Chen G, Zhang Z, Cao B, Han K, Yin J, Chu A, Zhao Y, Mao X*. A deuterated analog of dasatinib disrupts cell cycle progression and displays anti-non-small cell lung cancer activity in vitro and in vivo. Int J Cancer. 2012;131:2411-9.

[32]   Zhu J, Li Y, Yu H, Zhang L, Mao X*, Hou T*. Insight into the structural requirements of narlaprevir-type inhibitors of NS3/NS4A protease based on HQSAR and molecular field analyses. Comb Chem High Throughput Screen. 2012;15:439-50.

2011

[33]   Cao B, Mao X*. The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res. 2011;1(1):46-56.

[34]   Gan F#, Cao B#, Wu D, Chen Z, Hou T*, Mao X*. Exploring the old drugs for the therapeutics of hematological malignancies. Curr Med Chem, 2011;18:1509-14. Review.

[35]   Mao X*, Cao B, Wood TE, Hurren R, Tong J, Wang X, Wang W, Li J, Jin Y, Sun W, Spagnuolo PA, Maclean N, Moran MF, Datti A, Wrana J, Batey RA, Schimmer AD. A small molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway. Blood. 2011;117:1986-97.

[36]   Mao X*, Hou T, Cao B, Wang W, Li Z, Chen S, Fei M, Hurren R, Gronda M, Wu D, Trudel S, Schimmer AD. The tricyclic anti-depressant amitriptyline inhibits D-cyclin transactivation and induces myeloma cell apoptosis by inhibiting histone deacetylases:in vitro and in silico evidence. Mol Pharmacol. 2011;79:672-80.

2010

[37]   Li X, Wood TE, Sprangers R, Jansen G,  Franke NF, Mao X, Wang X, Zhang Y, VerbruggeSE, Li Z, Trudel S, Chen C, Jamal N, Messner H, Cloos J, Rose D, Navon A, Batey RA,  Kay LE,  Schimmer AD*. A non-competitive chemical proteasome inhibitor synergizes with and overcomes resistance to Bortezomib. J Natl Cancer Inst. 2010, 102:1069-82.

[38]    Xu GW, Ali M, Wood TE, Wong D, Maclean N, Wang X, Gronda M, Skrtic M, Li X, Hurren R, Mao X, Venkatesan M, Beheshti Zavareh R, Ketela T, Reed JC, Rose D, Moffat J, Batey RA, Dhe-Paganon S, Schimmer AD*. The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood. 2010, 115:2251-9.

[39]   Wood TE, Dalili S, Simpson CD, Sukhai MA, Hurren R, Anyiwe K, Mao X, Suarez Saiz F, Gronda M, Eberhard Y, MacLean N, Ketela T, Reed JC, Moffat J, Minden MD, Batey RA, Schimmer AD*. Selective inhibition of histone deacetylases sensitizes malignant cells to death receptor ligands. Mol Cancer Ther. 2010;9:246-56.

2009

[40]   Mao X#, Li X#, Sprangers M, Wang X, Vengopal A, Wood T, Zhang Y, Kuntz D, Coe E, Stewart AK, Roase D, Batey RA, Kay LE, and Schimmer AD*. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia. 2009;23:585-90.

[41]   Ren X, Mao X, Cao L, Xue K, Si L, Qiu J, Schimmer AD, Li G*.  Nonionic surfactants are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo. Eur J Pharm Sci. 2009;36(4-5):401-11.

[42]   Tiedemann RE*, Schmidt J, Shi CX , Zhu YX , Palmer SE, Mao X, Schimmer AD, Stewart AK. Identification of a potent natural triterpenoid inhibitor of proteosome chymotrypsin-like activity NF-kB with specific anti-myeloma activity in vitro and in vivo. Blood. 2009;113:4027-37.

2008

[43]   Mao X, Liang SB, Hurren R, Gronda M, Chow S, Xu GW, Wang X, Zavareh RB, Jamal N, Messner H, Hedley DW, Datti A, Wrana JL, Zhu Y, Shi CX, Lee K, Tiedemann R, Trudel S, Stewart AK, Schimmer AD*. Cyproheptadine displays preclinical activity in myeloma and leukemia. Blood. 2008;112:760-9.

[44]   Mao X, Zhu X, Hurren R, Ezzat S, and Schimmer AD*. Dexamethasone increases ubiquitin transcription through an SP-1 dependent mechanism in multiple myeloma cells. Leuk Res. 2008;32:1480-2.

[45]   Mao X, Schimmer AD*. The toxicology of Clioquinol. Toxicol Lett. 2008;182:1-6.

[46]   Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK*. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest. 2008;118:1750-64.

[47]   Zhu X, Mao X, Hurren R, Schimmer AD, Ezzat S, Asa SL*. Deoxyribonucleic acid methyltransferase 3B promotes epigenetic silencing through histone 3 chromatin modifications in pituitary cells. J Clin Endocrin & Metab. 2008;93:3610-7.

[48]   Ren X, Mao X, Si L, Cao L, Xiong H, Qiu J, Schimmer AD, Li G*. Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008;70:279-88.

[49]   Sprangers R, Li X, Mao X, Rubinstein JL, Schimmer AD, Kay LE*. TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors. Biochemistry. 2008; 47:6727-34.

[50]   Wood TE, Dalili S, Simpson CD, Hurren R, Mao X, Saiz FS, Gronda M, Eberhard Y, Minden MD, Bilan PJ, Klip A, Batey RA, Schimmer AD*.A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther. 2008;7:3546-55.

2007

[51]   Mao X, Stewart AK, Hurren R, Datti A, Zhu X, Zhu Y, Shi C, Lee K, Tiedemann R, Eberhard Y, Trudel S, Liang S, Corey S, Gillis L, Barber DL, Wrana J, Ezzat S, and Schimmer AD*. A chemical biology screen identifies glucocorticoids that regulate c-maf expression by increasing its proteasomal degradation through up-regulation of ubiquitin. Blood. 2007; 110:4047-54.

Before 2006

[52]   Yip KW, Mao X, Au PYB, Hedley DW, Chow S, Mocanu JD, Bastianutto C, Schimmer AD, Liu FF*. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen. Clin Cancer Res. 2006;12:5557--5569.

[53]   Yip KW, Ito E, Mao X, Au PY, Hedley DW, Mocanu JD, Bastianutto C, Schimmer A, Liu FF*. Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent. Mol Cancer Ther. 2006;5:2234-40.

[54]   Mao X, Seidlitz E, Ghosh K, Murakami Y, and Ghosh HP*. The cytoplasmic domain is critical to the tumor suppressor activity of TSLC1 in non-small cell lung cancer. Cancer Res. 2003; 63: 7979-7985.

[55]   Mao X, Seidlitz E, Truant R, Hitt M, and Ghosh HP*. Re-expression of TSLC1 in a non-small-cell lung cancer cell line induces apoptosis and inhibits tumor growth. Oncogene. 2004; 23:5632-42.

[56]   Mao X, Kashii T, Hayashi R, Sassa K, Fujishita T, Maruyama M, Kobayashi M, Liu S. Cloning of differentially expressed sequence tags from nickel-transformed human embryonic lung cells. Cancer Lett. 2000;161:57-62.

 

Book Chapter

1.      Mao X, Cao B. The Ubiquitin-Proteasomal System and Blood Cancer Therapy. Hematology- Science and Practice, Ed. By Charles H. Lawrie. InTech. 2012 March. pp. 497-516.

2.        曹碧茵,毛新良*。表观遗传学与抗肿瘤药物。高等药理学。丁健主编。科学出版社。2013

3.        毛新良*,曹碧茵。 泛素蛋白酶体系统与抗肿瘤药物研究。高等药理学。丁健院士主编。科学出版社。2013

 

3、课题

1)在研课题

[1]    国家自然科学基金(重大国际合作):多发性骨髓瘤细胞中大MAF 家族蛋白泛素化酶的蛋白组学分析及其病理学意义研究/ 813201080232014-2018

[2]    国家自然科学基金(面上项目):喹啉类药物对多发性骨髓瘤的实验性治疗作用及其抑制组蛋白去乙酰化酶的分子机理/812726322013-2016

[3]    国家重点基础研究发展计划(973计划)子课题:基于纳米材料的白血病病因和病理学研究/2011CB9335012011-2015

[4]    江苏省科技厅(科技支撑计划):一个新型PI3K靶向治疗恶性白血病药物的研制/BE2014630: 2014-2017

[5]    苏州市科技局支撑计划:新型PI3K靶向治疗恶性白血病药物的研制2014-2017

 

2)已经结题项目

[1]    国家自然科学基金(面上项目):转录因子c-maf泛素连接酶cMUL的鉴定及其在多发性骨髓瘤发生发展和治疗中的意义/810719352011-2013

[2]    江苏省自然科学基金(面上项目):新型PI3K抑制剂Picromin抗血液肿瘤的机理研究/ BK20102182010-2013

[3]    苏州市科技局科技支撑计划:抗抑郁药阿密曲替林治疗多发性骨髓瘤的研制/ SS2010332010-2013

 

4、专利

美国专利:

[1]       Inhibiting cyclin D polypeptides. US patent: US 8,822,440 B2. September 2, 2014. Inventors: Rodger E. Tiedemann, Alexander Keith Stewart, Aaron D. Schimmer, Xinliang Mao

[2]       Cyproheptadine for the treatment of acute myeloid leukemia and multiple myeloma.  US patent Serial No.: 60/889,881. Filed on Feb.19th, 2007. Inventors: Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.

[3]       Clioquinol as an oral copper-dependent inhibitor of the proteosome for the treatment of leukemia and multiple myeloma.  Serial No.:US60/980,783. Filed on Oct.18, 2007. Inventors:  Aaron D. Schimmer, Xinliang Mao, and Keith Stewart.

[4]       Pichromene for the treatment of hematological malignancies. Serial No.: US61/110,064.  Filed on Oct 31, 2008. Inventors: Aaron Schimmer, Xinliang Mao

[5]      Compounds for the treatment of hematological malignancies. Serial No.: US61/112,911. Filed on Nov 10, 2008. Inventors: Aaron Schimmer, Xiaoming Li, Robert Batey, Tabitha Wood ,Xinliang Mao

欧洲专利:

[6]       Clioquinol for the treatment of hematological malignancies. European Patent, Application Number: EP2211861. Publication Date:08/04/2010. Inventors: Aaron D. Schimmer,  Xinliang Mao, Keith Stewart.

国际专利:

[7]       Inhibiting cyclin D polypeptides, Pub. No.: WO/2008/045955. Publication date: 17.04.2008. Inventors: Rodger E. Tiedemann, Alexander Keith Stewart, Aaron D. Schimmer, Xinliang Mao.

[8]       Treatment of D-cyclin mediated proliferative diseases and hematological malignancies, Pub. No.: WO/2008/098351. Publication date: 21.08.2008. Inventors: Aaron D. Schimmer,  Xinliang Mao, Keith Stewart.

[9]       Clioquinol for the treatment of hematological malignancies. Pub. No.:WO/2009/049410. Publication  date: 23.04.2009. Inventors: Aaron D. Schimmer,  Xinliang Mao, Keith Stewart.  (该药经加拿大联邦卫生部批准进入临床I期实验。)

[10]   8-Hydroxyquinoline derivatives for the treatment of hematological malignancies.  PCT Application No.: PCT/CA2009/000776. Filed on 2009-05-06. Inventors: Aaron Schimmer, Xiaoming Li, Robert Batey, Tabitha Wood ,Xinliang Mao . (喹啉衍生物对恶性血液病的治疗作用)

中国专利:

[11] 一种磷脂酰肌醇-3-激酶抑制剂及其应用。中国国家知识产权局,专利申请号:ZL201010181572.6. 授权日期:20111109 发明人:毛新良;艾伦·什莫

[12]   3-硝基-8-乙氧基-2H-苯并吡喃类化合物及其制备方法与应用。中国国家知识产权局。专利申请号:ZL201210009328.0授权日期:20131127 发明人:刘兆鹏;尹树强;毛新良

[13]   2-(4-氟苯基)-3-硝基-8-乙氧基-2H-苯并吡喃手性化合物及其制备方法与应用. 中国国家知识产权局。201210005044.4. 申请日期:20120109 发明人: 刘兆鹏、尹树强、毛新良

[14]   一种8-乙氧基-2-(对氟苯基)-3-硝基-2H-苯并吡喃的制备方法。中国国家知识产权局。专利申请号:ZL201210132734.6授权日期:20150819。发明人:毛新良;刘兆鹏。

[15]   一种化合物的应用以及STAT3抑制剂。中国国家知识产权局。专利号:ZL ZL201210536766.2专利授予日期:2015114 发明人:许新;毛新良

[16]   一种PI3K小分子抑制剂及其应用。中国国家知识产权局。专利号:ZL 201310387348.6授权日期:20150121毛新良汤娟、朱景宇、俞洋、乔春华。

[17] 阿密曲替林的应用。中国国家知识产权局,专利申请号:2010101258347.  申请日期:201039 发明人:毛新良

[18]   一类新的STAT3小分子抑制剂及其应用。中国国家知识产权局。专利申请号:201310114357.8。申请日期:20130403 发明人:毛新良,杜晓林。

[19]   一种化合物及其制备与用途。中国国家知识产权局。专利申请号:201410191824.1。申请日期:20140508毛新良侯廷军、朱景宇。

[20]   一种化合物在其制备mTOR抑制剂中的应用。中国国家知识产权局。专利申请号:201510008720.7。申请日期:20150108毛新良韩昆昆。

[21]   一种血小板抑制剂及其在制备抗血小板疾病中的应用. 中国国家知识产权局。专利申请号:201510360965.6。申请日期:20150626曹碧茵、郝亚南、孔岩、徐耑、毛新良

四、主要荣誉和获奖情况

[1]      江苏医药杰出青年奖,江苏省药物研究与开发协会, 2015

[2]      江苏省科技进步一等奖,恶性血液肿瘤个体化诊疗新策略的建立和推广(排名第二),江苏省人民政府, 2015

[3]      高等学校科技进步一等奖:恶性血液肿瘤诊疗关键技术的创新和推广(排名第二),教育部, 2015

[4]      中华医学科技进步奖二等奖:造血干细胞移植治疗恶性血液肿瘤关键技术的优化和推广(排名第三),中华医学会,2015

[5]       江苏省“双创团队”核心成员,2014

[6]       苏州大学周氏教育科研奖优秀奖,2013

[7]       江苏省“333高层次人才培养工程培养对象,2011

[8]       苏州市紧缺高层次人才计划2009

[9]       加拿大Berlex生物医药研究奖 (Berlex Research Awards )2006

[10]   MCMM Fellowship, McLaughlin Centre for Molecular Medicine, Toronto, 2004

[11]   加拿大麦吉尔大学博士后奖学金(MCH postdoctoral fellowship, McGill University, Canada)2000

[12]   日本国际交流奖学金(Association of International Exchange Scholarship, Japan),1998

 

五、社会兼职

[1]      英国Nature出版社Scientific Reports 编委,2015

[2]      捷克国家科学基金评委, 2015

[3]       荷兰Current Pharmaceutical Design编委,客座编辑,2012

[4]       美国American Journal of Translational Research杂志编委,2012

[5]       中国药理学会生化与分子药理学专业委员会委员,2014

[6]       中国药理学会抗炎与免疫药理学专业委员会委员,2014

[7]       美国血液学学会(ASH)、美国药理学会(ASPET)和美国肿瘤研究学会(AACR)会员

[8]       美国药学会议Pharma2011组委会委员